机构地区:[1]首都医科大学附属北京安定医院,100088 [2]上海市精神卫生中心
出 处:《中华医学杂志》2010年第9期601-605,共5页National Medical Journal of China
基 金:北京市科技新星计划(2006A35);北京市卫生系统高层次人才培养计划(2009-3-53)
摘 要:目的随访首发精神分裂症患者感觉门控P50的特征,并分析P50指标与其临床症状间的关系。方法对58例首发精神分裂症患者(患者组)和108名正常对照(对照组)应用美国Nicolet Brova脑诱发电位仪进行听觉诱发电位P50检测,同时应用阳性和阴性症状量表(PANSS)对患者的精神症状评估,并随访3个月。结果(1)入组时,患者组感觉门控P50存在异常,表现为S2/S1高于对照组[Cz:对照组:0.43(0.27,0.58);患者组:0.77(0.58,1.04);Z=-9.23,P〈0.01],S1-S2的值小于对照组[Cz:对照组:2.65(1.55,4.79)μV;患者组:0.92(-0.13,2.32)μV;Z=-6.01,P〈0.01],(1-S2/S1)低于对照组[Cz:对照组:0.57(0.43,0.73);患者组:0.23(-0.04,0.42);Z=-10.61,P〈0.01]。(2)随访期间,患者组仍存在感觉门控P50异常。与对照组相比,患者组在Cz、Fz、Pz脑区的S2-P50波幅高,S2/S1高,S1-S2和(1-S2/S1)小,差异均有统计学意义(P〈0.05-0.01)。与入组时相比,患者随访期间在3个脑区的S2-P50波幅、S2/S1、S1-S2、(1-S2/S1)等指标无显著变化(P〉0.05)。患者组人组时的S1-P50波幅在Cz和Fz脑区低于对照组(Cz:患者组:4.1μV±2.1μV,对照组:5.6μV±3.3μV,t=-1.47,P=0.001;Fz:患者组:3.9μV±2.1μV,对照组:5.6μV±3.9μV,t=-1.63,P=0.003),随访到第3个月末时,Cz脑区的S1-P50波幅恢复正常,但Fz脑区的S1-P50波幅仍低于对照组(患者组:3.9μV±1.9μV,对照组:5.6μV±3.9μV,t=-1.62,P=0.03)。(3)随访到第3个月末时患者组的精神症状有所缓解和改善,表现为PANSS总分、阳性量表分、阴性量表分、一般精神病理量表分均有所减少(其分值分别为:入组时:138分±15分,33分±7分,41分±5分,65分±8分;随访3个月时:80分±15分�Objective To understand the variations of sensory gating P50 in naive schizophrenia during follow-up and the relations with positive and negative symptom scale (PANSS). Methods The data of auditory evoked potential P50 were recorded by USA Nicolet Brova instrument from 58 naive schizophrenia patients (Sch) and 108 normal controls (NC) at baseline, Months 1, 2 and 3 after treatment. And a simultaneous assessment of PANSS was made. Results ( 1 ) At baseline, as compared with NC, Sch group had a sensory gating deficit, reflected by a higher S2/S1 ( Cz : NC :0. 43 (0. 27, 0. 58) ; Sch : 0. 77 (0. 58, 1.04); Z=-9.23, P〈0.01), lower S1-S2 (Cz: NC: 2. 65(1.55, 4. 79)μV; Sch: 0.92( -0.13, 2. 32) μV ; Z = - 6. 01, P 〈 0. 01 ) and decreased more ( 1-S2/S1 ) ( Cz : NC :0. 57 (0. 43, 0. 73 ) ; Sch :0. 23 ( - 0. 04, 0. 42) ; Z = - 10. 61, P 〈 0. 01 ). (2) During follow-up, Sch group still had a sensory gating deficit. Compared with NC, Sch group had a more elevated S2-P50 amplitude, higher S2/S1, lower S1-S2 and (1-S2/S1) at Cz, Fz and Pz brain sites (P 〈0. 05-0. 01 ), and no significantly differences with S2-P50 amplitude, S2/S1, S1-S2 and ( 1-S2/S1 ) during follow-up (P 〉 0. 05). At baseline, Sch group had a much lowered S1-P50 amplitude than NC group at Cz and Fz brain sites (Cz: Sch: 4. 1 μV±2. 1 μV, NC: 5.6 μV±3.3 VV, t= - 1.47,P=0.001; Fz: Sch: 3.9 μV±2. 1 μV, NC: 5.6 txV±3.9 μV, t= - 1.63, P = 0. 003). At Month 3, Sch group showed an improved S1-P50 amplitude to normal level at Cz brain site, but S1-P50 amplitude improved at Fz brain site but it was lower than NC group (Sch: 3.9 μV ± 1.9 μV, NC: 5.6 μV±3.9 μV, t= -1.62, P=0.03). (3) At Month 3, Sch group showed a much lowered PANSS scale, positive symptom scale, negative symptom scale and general psychiatric symptoms scale than that at baseline (baseline: 138 ±15,33 ±7, 41 ±5, 65 ±8 ; Month 3 : 80 ± 15, 17 ±4,
分 类 号:R749.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...